Ophthalmology Clinical Trials This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the most recent publications within this specialty of the MedWorm directory.

Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients
Condition: CataractIntervention: Drug: Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solutionSponsors: Alcon Research; Alcon ResearchCompleted - verified May 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 20, 2013 Category: Research Source Type: clinical trials

The Molecular Pathogenesis of Fuchs' Endothelial Corneal Dystrophy
Condition: Fuchs' Endothelial DystrophyIntervention: Sponsors: Universitaire Ziekenhuizen Leuven; Universitaire Ziekenhuizen Leuven; Fund for Scientific Research, Flanders, Belgium; Funds for Research in Ophthalmology, Belgium; Mieke Perdaens fund for Eye ResearchRecruiting - verified January 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2013 Category: Research Source Type: clinical trials

R-Tech Ueno: Announcement of Approval of sNDA for RESCULA Ophthalmic Solution and Start of Commercialization
TOKYO--(BUSINESS WIRE)--Dec 19, 2012 - R-Tech Ueno (JASDAQ:4573): Sucampo Pharmaceuticals, Inc. (hereinafter referred to as "Sucampo") announced that it has received approval by the U.S. Food and Drug Administration (FDA) of the supplemental new... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 21, 2012 Category: Pharmaceuticals Source Type: clinical trials

Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group
Condition: Dry Eye SyndromesIntervention: Drug: Cyclosporine ophthalmic solutionSponsors: Hanlim Pharm. Co., Ltd.; Hanlim Pharm. Co., Ltd.Recruiting - verified January 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 10, 2012 Category: Research Source Type: clinical trials

A Phase 2, Double-masked, Randomized, Multi-center, Active-controlled, Dose-response Parallel-group Study Comparing the Safety and Ocular Hypotensive Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
Conditions: Ocular Hypertension; Open Angle GlaucomaInterventions: Drug: AR-13324 Ophthalmic Solution 0.01%; Drug: AR-13324 Ophthalmic Solution 0.02%; Drug: Latanoprost ophthalmic solutionSponsors: Aerie Pharmaceuticals; Aerie PharmaceuticalsRecruiting - verified November 2012 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2012 Category: Research Source Type: clinical trials

A Phase 2, Double-masked, Randomized, Multi-center, Active-controlled, Dose-response Parallel-group Study Comparing the Safety and Ocular Hypotensive Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
Conditions: Ocular Hypertension; Open Angle GlaucomaInterventions: Drug: AR-13324 Ophthalmic Solution 0.01%; Drug: AR-13324 Ophthalmic Solution 0.02%; Drug: Latanoprost ophthalmic solutionSponsors: Aerie Pharmaceuticals; Aerie PharmaceuticalsActive, not recruiting - verified January 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2012 Category: Research Source Type: clinical trials